Australia markets open in 2 hours 5 minutes

Lysogene S.A. (LYSGF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
3.50000.0000 (0.00%)
At close: 10:57AM EDT

Lysogene S.A.

18-20 rue Jacques Dulud
Neuilly-sur-Seine 92200
33 1 41 43 03 90

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 

Key executives

NameTitlePayExercisedYear born
Ms. Karen Pignet-Aiach MBAFounder, Chairman & CEO493.28kN/A1971
Mr. Stephane Durant des AulnoisAdmin. & Financial DirectorN/AN/AN/A
Dr. Ralph LauferChief Scientific OfficerN/AN/AN/A
Dr. MichaΓ«l Hocquemiller Ph.D.Head of Non-Clinical Devel.N/AN/AN/A
Dr. Marie DeneuxChief Regulatory affairsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was incorporated in 2009 and is based in Neuilly-sur-Seine, France.

Corporate governance

Lysogene S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.